Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System Academic Article uri icon

abstract

  • Abstract Purpose When levodopa (L-DOPA) is administered orally, it is eliminated from the body very quickly resulting in a series of sharp fluctuations in its blood concentrations. These frequent changes in blood levels are considered to be responsible for the development of late motor complications and dyskinesias, which are troubling clinical and treatment issues in Parkinson's disease. Transdermal drug delivery is a patient-compliant method for delivering therapeutics into the systemic circulation in a continuous and controlled manner. Transdermal delivery of L-DOPA can achieve continuous dopaminergic stimulation (CDS), thus reducing motor fluctuations. Methods However, there are two technical difficulties in the development of a transdermal patch for L-DOPA:(a) L-DOPA is poorly soluble in most pharmaceutically-acceptable solvents, and (b) L-DOPA has a limited permeability through …

publication date

  • April 12, 2017